Respiratory patient groups see pharma's reputation as boosted in 2022, but decry pricing, access to lung meds

Patient groups focused on lung diseases have observed an overall improvement in the pharmaceutical industry’s reputation in 2022 compared to the previous year. | Patient groups focused on lung diseases have observed an overall improvement in the pharmaceutical industry’s reputation in 2022 compared to the previous year. Nevertheless, they continue to identify two major concerns for respiratory diseases—pricing and access to medicines—which remain unresolved.